February 7, 2014
Protease Inhibitors Make a First Splash
The first wave of new HCV drugs arrived in the form of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), which were approved in the U.S. in 2011 for the treatment of HCV genotype 1. They have not yet been approved specifically for HIV-coinfected patients, however -- and Cox suggested that their day in the sun may be setting.
In clinical trials, boceprevir and telaprevir have both been shown to dramatically increase HCV treatment success rates in therapy-naive, HIV-coinfected patients. But they still must be taken with interferon, and both drugs have been found to exacerbate the adverse effects seen among patients taking interferon-based therapies. Between those sobering data and extensive drug-interaction concerns with HIV medications, "it's not easy to take these medications," Cox said.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|CDC Corrects Misleading HIV Conception Guidance, Responding to Community Pressure|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|New York Study Finds Almost Half of HIV-Positive Gay Men Co-Infected With Hepatitis C Have Detectable Levels of Hepatitis C Virus in Their Rectal Fluid|
|This Week in HIV Research: A New Glimpse Into HAND|
|This Week in HIV Research: New Discovery in How HIV Hijacks a Cell|
|Research in New York Confirms That MSM Will Likely Follow Up After a Positive at-Home HIV Test|